Visit the Website for Patients 
Français
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec
Approval Performances
NEPTUNUS-2
Auto-immune Diseases Phase III
- 8.6 weeks
- 1st site activated in Canada and Canadian FPI
NEPTUNUS-2
Auto-immune Diseases Phase III
- 14.3 weeks
- 2nd site activated in Canada
ONWARDS
Arthritis Phase II
- 9.1 weeks
- Ongoing study
PKM16982
Urticaria Phase III
- 8.4 weeks
- 2nd site activated in Canada
STRENGTH
Spinal Muscular Atrophy Phase II
- 12.1 weeks
- 1st site activated in Canada